Pfizer ai News

For the fourth time in half as many years, Anumana has earned the FDA’s breakthrough device designation for another of its artificial intelligence algorithms designed to catch hard-to-spot heart co | For the fourth time in half as many years, Anumana has earned the FDA’s breakthrough device designation for another of its artificial intelligence algorithms…

Cerevel and Pfizer are using the Target and Lead Identification Suite—and Colossal Biosciences is adopting the Multiomics Suite—to bring therapeutics to market faster BOSTON , May 16, 2023 /PRNewswire/ -- Today at the Bio-IT World Conference, Google Cloud announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine…

A research team from the Korea Advanced Institute of Science and Technology has developed an AI model to predict adverse reactions between oral anti-COVID-19 medication and prescription drugs. Researchers from KAIST's Department of Biochemical Engineering made a new version of the DeepDDI AI-based drug interaction prediction model to check how ritonavir and nirmatrelvir, two components…

Welcome to the latest edition of Investigative Roundup, highlighting some of the best investigative reporting on healthcare each week. Pfizer CEO Maxed Out Political Contributions to Mehmet Oz Pfizer CEO Albert Bourla, PhD, made the maximum possible campaign contribution to Mehmet Oz, MD, in his run for U.S. Senate, STAT reported, citing federal campaign finance…

Tempus, a leader in artificial intelligence (AI) and precision medicine, today announced a multi-year, strategic collaboration with Pfizer in which th

Tempus, a provider in artificial intelligence (AI) and precision medicine, has entered a multi-year, strategic collaboration with Pfizer to further AI and machine learning-driven efforts in therapeutic development. The collaboration aims to more precisely gather insights that will inform novel drug discovery and development in oncology.   Through this collaboration, Pfizer has access to Tempus’…

Agreement centered around the use of artificial intelligence (AI) to advance cancer drug efficacy assessment. BOSTON , Feb. 21, 2023 /PRNewswire/ -- Vysioneer, a pioneer in AI for Oncology, today announced a data sharing agreement with Pfizer, a global leader in pharmaceuticals. The agreement aims to lay the foundation for the application…

The company is modernizing clinical trials in order to reimagine the patient experience

Head over to our on-demand library to view sessions from VB Transform 2023. Register Here Getting COVID-19 isn’t fun, but the key to getting better faster has a lot to do with getting treatment faster. Digital health vendor Ada Health today announced that it has partnered with drugmaker Pfizer on an artificial intelligence (AI)-assisted application…

Technion-Israel Institute of Technology and Pfizer, one of the world’s leading biopharmaceutical companies, recently signed a collaboration framework agreement to identify opportunities to collaborate and bring forward scientific breakthroughs at the interface between artificial intelligence and drug development. The framework agreement was finalized during the visit of a delegation from Pfizer to…

Pfizer's Cambridge, Massachusetts site/courtesy of Pfizer  Artificial intelligence and machine learning (AI/ML) are key to enabling drug discovery and development, and Pfizer is leading the biopharma industry into the next wave of innovation. The company is rapidly scaling up and recruiting talent for a collaborative effort intended to get transformative medicines to patients faster.   …

The heart-focused artificial intelligence company Anumana is looking to break new ground for its algorithms through a partnership with Pfi | Anumana has staked a claim on the idea that there is a wealth of data still to be mined from reading into the electrical activity of the heart.